Eltrombopag

For research use only. Not for use in humans.

目录号:S4502 别名: SB-497115 中文名称:艾曲波帕

Eltrombopag  Chemical Structure

CAS No. 496775-61-2

Eltrombopag (SB-497115),属于biarylhydrazone小分子,是一种thrombopoietin receptor (TpoR)的非肽类激动剂,用于治疗慢性丙型肝炎相关的血小板减少和慢性免疫性(自发的)血小板减少(ITP)。

规格 价格 库存 购买数量  
RMB 806.02 现货
RMB 2445.87 现货
RMB 5716.72 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Eltrombopag 发表文献6篇:

客户使用该产品的2个实验数据:

  • 32D‐MPL cells were treated with hetrombopag (10 nmol/L), eltrombopag (100 nmol/L) or rhTPO (10 ng/mL) for the indicated time. Whole‐cell lysates were analysed by Western blotting using the indicated antibodies.

    J Cell Mol Med, 2018, 22(11):5367-5377. Eltrombopag purchased from Selleck.

    Effect of eltrombopag on cell cycle progression in Huh7 cells. (A) Cells were treated with EP (0 and 10 μg/ml) for 72 h. DNA was stained with propidium iodide, and flow cytometric analysis of cell phase distribution was performed using a Muse™ cell analyzer. (B) Cells were treated with EP (0, 1 and 10 μg/ml) for 72 h. Protein expression was determined by western blot analysis using anti-cyclin D1, anti-p21 and anti-GAPDH antibodies. SDS-PAGE was performed on acrylamide gels.

    Int J Oncol, 2015, 47(5):1696-702.. Eltrombopag purchased from Selleck.

产品安全说明书

TpoR抑制剂选择性比较

生物活性

产品描述 Eltrombopag (SB-497115),属于biarylhydrazone小分子,是一种thrombopoietin receptor (TpoR)的非肽类激动剂,用于治疗慢性丙型肝炎相关的血小板减少和慢性免疫性(自发的)血小板减少(ITP)。
靶点
thrombopoietin receptor (TpoR) [1]
体外研究

含有STAT激活的IRF-1启动子和人TpoR (BAF3/IRF-1/hTpoR)调控的转染荧光素酶报告基因的小鼠BAF3细胞中,Eltrombopag表现出的半数最大有效浓度(EC50) 为0.27 μM。Eltrombopag通过结合金属铁(i.e., Zn2+)和TpoR的跨膜与近膜结构域内特异性氨基酸,从而激活受体。抗磷酸- STAT5抗体免疫印迹检测表明,Eltrombopag (30 μM)激活N2C-Tpo 细胞中STAT5。培育2天后,Eltrombopag刺激增殖,对BAF3/hTpoR细胞进行BrdU测定,EC50为0.03 μM。Eltrombopag也会诱导造血干细胞分化为巨核祖细胞。Eltrombopag剂量依赖性增加骨髓CD34+细胞分化为CD41+巨核细胞,EC50为0.1 μM。[1] Eltrombopag抑制N2C-Tpo细胞和HEL92.1.7细胞增殖,IC50分别为20.7 μg/mL和2.3 μg/mL。[2]在人和小鼠白血病细胞中,Eltrombopag (20 μg/mL)导致细胞分裂率减少,细胞周期G(1)期阻滞,以及细胞分化增加。HL60 细胞中,Eltrombopag (5 μg/mL)表现出明显的分化信号,显著改变细胞核内容物的结构,并增加细胞质/细胞核比率。Eltrombopag (5 μg/mL)增加CD11b,这与U937细胞中前巨噬细胞状态一致,并引起URE细胞中CD11b的增加。白血病HL60细胞中,Eltrombopag导致细胞内游离铁离子剂量依赖性减少。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Ba/F3 NUnHSHRkTnWwY4Tpc44h[XO|YYm= M3T1UmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6geIhzd22kb4DvbYV1cW5icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJI1wfXOnIFLhM2Y{KGOnbHzzJIJ6KGurbnHz[UBi[3SrdnH0bY9vKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xOzkQvF2= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd6M{m0PUc,OTh5OEO5OFk9N2F-
Ba/F3 MmHkSpVv[3Srb36gZZN{[Xl? MlzTRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjD0bJJwdWKxcH;p[ZRqdiC{ZXPldJRweiCrbjDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyCjY4TpeoF1cW:wIH;mJHN1[XR3IILld5BwdnOnIHXs[Y1mdnRvZILpeoVvKHKncH;yeIVzKGenbnWg[ZhxemW|c3nvckwhTUN3ME2wMlA{QM7:TR?= Mon1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5N{i5N|YoRjF6N{e4PVM3RC:jPh?=
HEK293/PDZK1 NXm0XnNmTnWwY4Tpc44h[XO|YYm= NWn3XnlnUW6qaXLpeIlwdiCxZjDPRXRROkJzLX3l[IlifGWmIGuzTH1me3S{b37lMVMue3WuZnH0[UB2eHSja3WgbY4hcHWvYX6gU2FVWDKEMTDlfJBz\XO|aX7nJGhGUzJ7Mz;QSHpMOSClZXzsd{BjgSC|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcT16LkS4{txO MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2MkKxPVEoRjJzNEKyNVkyRC:jPh?=
HEK293/PDZK1 MX;GeY5kfGmxbjDhd5NigQ>? Ml3kTY5pcWKrdHnvckBw\iCRQWTQNWIyNW2nZHnheIVlKFt|SG3ld5Rzd26nLUOtd5Vt\mG2ZTD1dJRic2ViaX6gbJVu[W5iT1HUVFFDOSCneIDy[ZN{cW6pIFjFT|I6Oy:SRGrLNUBk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbV0yPC57zszN NXzP[25IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0NlIyQTFpPkKxOFIzOTlzPD;hQi=>
HEK293/PDZK1 NVvqcFdVTnWwY4Tpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKE:DVGCxRlMudWWmaXH0[YQhYzOKXXXzeJJi\GmxbDCxO4JmfGFvZ3z1Z5Vzd26rZHWgeZB1[WunIHnuJIh2dWGwIF;BWHAySjNiZYjwdoV{e2mwZzDISWszQTNxUFTaT|Eh[2WubIOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4k:OjVwNt88US=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR{MkG5NUc,OjF2MkKxPVE9N2F-
HEK293/PDZK1 NV;GXGR[TnWwY4Tpc44h[XO|YYm= MoLrTY5pcWKrdHnvckBw\iCRQWTQNWI{NW2nZHnheIVlKFt|SG3ld5Rz[WSrb3ygNVdj\XSjLXfseYN2em:waXTlJJVxfGGtZTDpckBpfW2jbjDPRXRROUJ|IHX4dJJme3OrbnegTGVMOjl|L2DEXmsyKGOnbHzzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbne= M3;nV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEKyNVkyLz5{MUSyNlE6OTxxYU6=
HEK293/PDZK1 NUm3N|VrTnWwY4Tpc44h[XO|YYm= MoLsTY5pcWKrdHnvckBw\iCRQ2SxMY1m\GmjdHXkJHsyPEOfdHX0doFmfGi7bHHtcY9vcXWvIIXweIFs\SCrbjDoeY1idiCRQ2SxJIV5eHKnc4PpcochUEWNMkmzM3BFYktzIHPlcIx{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoc> M{\kR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEKyNVkyLz5{MUSyNlE6OTxxYU6=
HEK293/PDZK1 MWXGeY5kfGmxbjDhd5NigQ>? NIfhUI4{OCCvaX7z MmrqSJJ2\yC3cIThb4UhcW5iaIXtZY4hV0GWUEHCNUBmgHC{ZYPzbY5oKEiHS{K5N{9RTFqNMTDj[YxteyCjdDCzO{Bl\WeFIH\vdkA{OCCvaX7z NXTvNW1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0NlIyQTFpPkKxOFIzOTlzPD;hQi=>
HEK293/PDZK1 Mn7nSpVv[3Srb36gZZN{[Xl? NXL3dm9{OzBibXnudy=> MlraSJJ2\yC3cIThb4UhcW5iaIXtZY4hV0GWUELCNUBmgHC{ZYPzbY5oKEiHS{K5N{9RTFqNMTDj[YxteyCjdDCzO{Bl\WeFIH\vdkA{OCCvaX7z NHTGN2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSyNlE6OSd-MkG0NlIyQTF:L3G+
HEK293/PDZK1 NHywTIlHfW6ldHnvckBie3OjeR?= NF7GUFE{OCCvaX7z NHfxO2JFenWpIIXweIFs\SCrbjDoeY1idiCRQ2SxJIV5eHKnc4PpcochUEWNMkmzM3BFYktzIHPlcIx{KGG2IEO3JIRm\0NiZn;yJFMxKG2rboO= NHP4[VE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSyNlE6OSd-MkG0NlIyQTF:L3G+
HEK293/PDZK1 MXLGeY5kfGmxbjDhd5NigQ>? MonjTY5pcWKrdHnvckBw\iCRQWTQNWIyNW2nZHnheIVlKFt|SG3ld5Rzd26nLUOtd5Vt\mG2ZTD1dJRic2ViaX6gbJVu[W5iT1HUVFFDOSCneIDy[ZN{cW6pIFjFT|I6Oy:SRGrLNUBk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6p NIjuOpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSyNlE6OSd-MkG0NlIyQTF:L3G+
HEK293/PDZK1 MWDGeY5kfGmxbjDhd5NigQ>? MnjZTY5pcWKrdHnvckBw\iCRQWTQNmIyNW2nZHnheIVlKFt|SG3ld5Rzd26nLUOtd5Vt\mG2ZTD1dJRic2ViaX6gbJVu[W5iT1HUVFJDOSCneIDy[ZN{cW6pIFjFT|I6Oy:SRGrLNUBk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6p NUfxfm81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0NlIyQTFpPkKxOFIzOTlzPD;hQi=>
DAOY NYLvNHFpeUiWUzDhd5NigQ>? NHe2SotyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NUfQOGRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 M3vqNJFJXFNiYYPzZZk> MkHudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC M1;GWZFJXFNiYYPzZZk> NGnQVGtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NEDwc3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NIPObVVyUFSVIHHzd4F6 NIq4OnVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= M1;pblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NGOzNIJyUFSVIHHzd4F6 NUDxd|RqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> MoHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 Mk\GdWhVWyCjc4PhfS=> M3T1eJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MXnxTHRUKGG|c3H5 MlnZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NEXze|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) NUK1cJJ5eUiWUzDhd5NigQ>? MoSxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| M3PscFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NViz[2NIeUiWUzDhd5NigQ>? NETGdmVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= NWf2d21rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
VERO-E6 NGnLXpBHfW6ldHnvckBie3OjeR?= NWP1SY9DPDhiaILz NHLWdZhVd3irY3n0fUBESzVyIHHnZYlve3RiVlXSU{1GPiClZXzsd{Bl\XSncn3pcoVlKGG2IES4JIhwfXK|IHL5JIhq\2hiY3;ueIVvfCCrbXHnbY5oKCi|YX3lJINwdmSrdHnvcpMh[XNiMm;MSXkhf2m2aH;1eEBmgHCxc4Xy[UB1dyByLkCxJG1QUSCVQWLTJGNwXi1{II\pdpV{MSxiQ1O1NF0{NjJ4zszN MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OlEyODFxJ{7DbGVOSkx:L3G+
Vero M4m2RWFvfGm4aYLhcEBie3OjeR?= MV:yOEBpenN? MknHRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgV2FTWy2Fb2[tNkApfmm{YXygeIl1\XJrIH3lZZN2emWmIHL5JJBt[XG3ZTDhd5NigSCrbjDW[ZJwKGOnbHzzJIF1KE2RSTCwMlAyOjViYX\0[ZIhOjRiaIKsJGlEPTB;OD6yO:69VQ>? NEHmV2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PjFzMEGvK|5EcEWPQly8M4E,

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT5 / STAT5 / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 30156363     


32D‐MPL cells were treated with hetrombopag (10 nmol/L), eltrombopag (100 nmol/L) or rhTPO (10 ng/mL) for the indicated time. Whole‐cell lysates were analysed by Western blotting using the indicated antibodies

p-RB / RB / CDK4 / CDK6 / Cyclin D1 ; 

PubMed: 30156363     


After treatment of 32D‐MPLcells with hetrombopag, eltrombopag or 10 ng/mL rhTPO for 24 hours, whole‐cell lysates were immunoblotted with the indicated antibodies. 

30156363
Growth inhibition assay
Cell viability; 

PubMed: 31564981     


Viability of K562 cells incubated with EP (2.5, 5, 10 and 30 μg/mL) alone for 24, 48, 72 and 96 hrs. 

31564981
体内研究 Eltrombopag (10 mg/kg每天) 最后一次给药1周后,使一只黑猩猩体内的血细胞数量大约增加超过2倍,另外两只黑猩猩体内大约增加1.5倍。[1] Eltrombopag (1 mg/mL)延长白血病小鼠模型的存活时间。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 26 mg/mL warmed (58.76 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 442.47
化学式

C25H22N4O4

CAS号 496775-61-2
储存条件 粉状
溶于溶剂
别名 SB-497115

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04797000 Recruiting Drug: Eltrombopag|Drug: Placebo Myelodysplastic Syndromes Novartis Pharmaceuticals|Novartis May 25 2021 Phase 2
NCT04600960 Recruiting Drug: Eltrombopag Chemotherapy-induced Thrombocytopenia|Eltrombopag Institute of Hematology & Blood Diseases Hospital December 31 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买Eltrombopag | Eltrombopag ic50 | Eltrombopag 价格 | Eltrombopag DMSO溶解度 | 采购Eltrombopag | Eltrombopag 生产 | Eltrombopag 小鼠 | Eltrombopag 化学结构 | Eltrombopag 分子量 | Eltrombopag molecular weight | Eltrombopag 说明书 | Eltrombopag 供应商 | Eltrombopag 体内 | Eltrombopag 细胞系 | Eltrombopag 浓度 | Eltrombopag nmr | Eltrombopag 核磁 | Eltrombopag 半数抑制浓度 | Eltrombopag 体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID